Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Fentolamin
2. Mesilate, Phentolamine
3. Mesylate, Phentolamine
4. Methanesulfonate, Phentolamine
5. Mono-hydrochloride, Phentolamine
6. Phentolamine
7. Phentolamine Mesilate
8. Phentolamine Methanesulfonate
9. Phentolamine Mono Hydrochloride
10. Phentolamine Mono-hydrochloride
11. Regitine
12. Regityn
13. Rogitine
14. Z-max
1. 65-28-1
2. Phentolamine Mesilate
3. Phentolamine Methanesulfonate
4. Phentolamine (mesylate)
5. Oraverse
6. Regitine Mesylate
7. Phentolamine Methanesulfonate Salt
8. Phentolamine Mesylate [usp]
9. Mesylate Phentolamine
10. 3-(((4,5-dihydro-1h-imidazol-2-yl)methyl)(p-tolyl)amino)phenol Methanesulfonate
11. Nv-101
12. Mls000069487
13. Y7543e5k9t
14. M-(n-(2-imidazolin-2-ylmethyl)-p-toluidino)phenol Monomethanesulfonate (salt)
15. Phenol, 3-(((4,5-dihydro-1h-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, Monomethanesulfonate (salt)
16. Phenol,3-[[(4,5-dihydro-1h-imidazol-2-yl)methyl](4-methylphenyl)amino]-,monomethanesulfonate (salt)
17. Smr000059054
18. 3-[n-(4,5-dihydro-1h-imidazol-2-ylmethyl)-4-methylanilino]phenol;methanesulfonic Acid
19. Phentolamine Mesylate (usp)
20. Vasomax
21. Regitin Methanesulphonate
22. Regitine Methanesulfonate
23. Phenol, M-[n-(2-imidazolin-2-ylmethyl)-p-toluidino]-, Methanesulfonate (1:1)
24. Phentolamine Methanesulphonate
25. Ccris 9022
26. Phentolamine Mesilate [inn:ban]
27. Einecs 200-604-6
28. Vasofem
29. Unii-y7543e5k9t
30. Regitin Mesylate
31. Sr-01000000055
32. Regitine (tn)
33. Z-max
34. Mfcd00134201
35. Opera_id_1599
36. Lopac-p-7561
37. Phentolamine Meslate,(s)
38. Schembl40852
39. Mls001076484
40. Phentolamine, Methyl Sulfonate
41. Regid_for_cid_91430
42. Chembl1200873
43. Hy-b0362a
44. Dtxsid60215315
45. Phentolamine Mesilate (jan/inn)
46. Hms2233a24
47. Hms3263e05
48. Hms3373d03
49. Hms3655b13
50. Hms3884a22
51. Phentolamine Mesilate [jan]
52. Bcp09845
53. Tox21_500982
54. Phentolamine Mesylate [vandf]
55. S2038
56. 3-fluoropyridine-4-boronicacidhydrate
57. Phentolamine Mesilate [mart.]
58. Akos007930193
59. Phentolamine Mesilate [who-dd]
60. Phentolamine Mesylate [usp-rs]
61. Ac-7472
62. Ccg-222286
63. Lp00982
64. 3-[n-(4,5-dihydro-1h-imidazol-2-ylmethyl)-4-methylanilino]phenol; Methanesulfonic Acid
65. Phenol, M-(n-(2-imidazolin-2-ylmethyl)-p-toluidino)-, Monomethanesulfonate (salt)
66. Ncgc00016195-01
67. Ncgc00016195-02
68. Ncgc00094282-01
69. Ncgc00261667-01
70. As-13800
71. Phentolamine Methanesulfonate [mi]
72. Phentolamine Mesylate [orange Book]
73. Phentolamine Mesilate [ep Monograph]
74. Eu-0100982
75. Ft-0603267
76. P1985
77. Phentolamine Mesylate [usp Monograph]
78. Sw196637-3
79. D00509
80. P 7561
81. T72782
82. 134p201
83. A835046
84. Sr-01000000055-3
85. W-104799
86. Q27294332
87. Phentolamine Methanesulfonate Salt, >=98% (tlc), Powder
88. Phentolamine Mesilate, British Pharmacopoeia (bp) Reference Standard
89. 2-[n-(m-hydroxyphenyl)-p-toluidinomethyl]imidazoline Methanesulfonate
90. Phentolamine Mesilate, European Pharmacopoeia (ep) Reference Standard
91. Phentolamine Mesylate, United States Pharmacopeia (usp) Reference Standard
92. 3-(((4,5-dihydro-1h-imidazol-2-yl)methyl)(p-tolyl)amino)phenolmethanesulfonate
93. 3-[[(4,5-dihydro-1h-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol Methanesulfonate
94. 3-[4,5-dihydro-1h-imidazol-2-ylmethyl-(4-methylphenyl)amino]phenol; Methanesulfonic Acid
95. 3-[n-(4,5-dihydro-1h-imidazol-1-ium-2-ylmethyl)-4-methylanilino]phenol;methanesulfonate
96. M-(n-(2-imidazolin-2-ylmethyl)-p-toluidino)phenol Monomethanesulphonate (salt)
97. Phentolamine Mesilate For System Suitability, European Pharmacopoeia (ep) Reference Standard
98. Phentolamine Mesylate, Pharmaceutical Secondary Standard; Certified Reference Material
99. Phenol, 3-(((4,5-dihydro-1h-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, Monomethanesulphonate (salt)
Molecular Weight | 377.5 g/mol |
---|---|
Molecular Formula | C18H23N3O4S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 377.14092740 g/mol |
Monoisotopic Mass | 377.14092740 g/mol |
Topological Polar Surface Area | 111 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 456 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Phentolamine mesylate |
Drug Label | Phentolamine Mesylate for Injection USP, is an antihypertensive, available in vials for intravenous and intramuscular administration. Each vial contains phentolamine mesylate USP, 5 mg and mannitol USP, 25 mg in sterile, lyophilized form.Phentolamine... |
Active Ingredient | Phentolamine mesylate |
Dosage Form | Injectable |
Route | Injection |
Strength | 5mg/vial |
Market Status | Prescription |
Company | Eurohlth Intl |
2 of 4 | |
---|---|
Drug Name | Oraverse |
PubMed Health | Phentolamine (Injection) |
Drug Classes | Antihypertensive, Diagnostic Agent, Pheochromocytoma, Toxicology-Antidote Agent |
Drug Label | Phentolamine mesylate is phenol,3-[[(4,5-dihydro-1 H-imidazol-2-yl)methyl](4-methyl-phenyl)amino]-, methanesulfonate (salt), a non-specific alpha adrenergic blocker.Phentolamine mesylate USP is a white to off-white, odorless crystalline powder with a... |
Active Ingredient | Phentolamine mesylate |
Dosage Form | Injectable |
Route | Injection |
Strength | 0.4mg/1.7ml |
Market Status | Prescription |
Company | Septodont Holding |
3 of 4 | |
---|---|
Drug Name | Phentolamine mesylate |
Drug Label | Phentolamine Mesylate for Injection USP, is an antihypertensive, available in vials for intravenous and intramuscular administration. Each vial contains phentolamine mesylate USP, 5 mg and mannitol USP, 25 mg in sterile, lyophilized form.Phentolamine... |
Active Ingredient | Phentolamine mesylate |
Dosage Form | Injectable |
Route | Injection |
Strength | 5mg/vial |
Market Status | Prescription |
Company | Eurohlth Intl |
4 of 4 | |
---|---|
Drug Name | Oraverse |
PubMed Health | Phentolamine (Injection) |
Drug Classes | Antihypertensive, Diagnostic Agent, Pheochromocytoma, Toxicology-Antidote Agent |
Drug Label | Phentolamine mesylate is phenol,3-[[(4,5-dihydro-1 H-imidazol-2-yl)methyl](4-methyl-phenyl)amino]-, methanesulfonate (salt), a non-specific alpha adrenergic blocker.Phentolamine mesylate USP is a white to off-white, odorless crystalline powder with a... |
Active Ingredient | Phentolamine mesylate |
Dosage Form | Injectable |
Route | Injection |
Strength | 0.4mg/1.7ml |
Market Status | Prescription |
Company | Septodont Holding |
Adrenergic alpha-Antagonists
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39948
Submission : 2024-06-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11936
Submission : 1996-04-19
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-01-10
Pay. Date : 2012-12-21
DMF Number : 16428
Submission : 2003-02-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39578
Submission : 2024-03-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12260
Submission : 1996-12-11
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-10-28
Pay. Date : 2014-06-12
DMF Number : 28193
Submission : 2014-06-16
Status : Active
Type : II
Certificate Number : R1-CEP 2001-442 - Rev 02
Status : Valid
Issue Date : 2010-12-03
Type : Chemical
Substance Number : 1138
Date of Issue : 2022-07-15
Valid Till : 2025-07-02
Written Confirmation Number : WC-0110n
Address of the Firm : 252-253, Dhobikuva-391 440, Opp.Jain Irrigation, Padra Jambusar Highway, Tal.Pad...
NDC Package Code : 42973-389
Start Marketing Date : 2024-04-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SOLUTION (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 42973-194
Start Marketing Date : 2012-09-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 73212-028
Start Marketing Date : 2023-01-02
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63190-0090
Start Marketing Date : 2003-02-13
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60592-602
Start Marketing Date : 2023-10-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51927-0176
Start Marketing Date : 2018-09-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 90027-005
Start Marketing Date : 2022-06-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 90027-005
Start Marketing Date : 2021-01-07
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 82139-0009
Start Marketing Date : 2022-10-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59605-2260
Start Marketing Date : 1996-12-11
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Laboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.
About the Company : Laboratorium Ofichem is a GMP-certified and FDA-approved API manufacturer with state-of-the-art development and production facilities in the Netherlands. We develop and manufacture...
About the Company : More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, ...
About the Company : Jiangsu Lianhuan Pharmaceutical Co., Ltd. was founded in 2000. It is a state-controlled competitive listed company. Its predecessor was Yangzhou Pharmaceutical Factory, which was e...
About the Company : Shouyuan chemical (one of the leading chemicals supplier in China) specializes in manufacturing, supplying, and custom synsthesis latest chemicals. Our products cover all kinds of ...
About the Company : In November 2020, Viatris was formed through the combination of Mylan and Upjohn, with a mission of empowering people worldwide to live healthier at every stage of life. Viatris (N...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Nyxol (phentolamine ophthalmic solution) is an adrenergic receptor antagonist. It is being evaluated for the treatment Presbyopia.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Brand Name: Nyxol
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2024
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial of Phentolamine for Presbyopia
Details : Nyxol (phentolamine ophthalmic solution) is an adrenergic receptor antagonist. It is being evaluated for the treatment Presbyopia.
Brand Name : Nyxol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 05, 2024
Details:
Nyxol (phentolamine mesylate ophthalmic solution) is an alpha1/2 adrenergic receptor inhibitor being investigated in Phase 3 for decreased visual acuity under low light after keratorefractive surgery.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Brand Name: Nyxol
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
First Patient Enrolled in LYNX-2 Phase 3 Study for Phentolamine Ophthalmic Solution
Details : Nyxol (phentolamine mesylate ophthalmic solution) is an alpha1/2 adrenergic receptor inhibitor being investigated in Phase 3 for decreased visual acuity under low light after keratorefractive surgery.
Brand Name : Nyxol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2024
Details:
Ryzumvi (phentolamine mesylate) is an alpha adrenergic blocker indicated for treating pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents like tropicamide.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Brand Name: Ryzumvi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Viatris Launches RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in The U.S.
Details : Ryzumvi (phentolamine mesylate) is an alpha adrenergic blocker indicated for treating pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents like tropicamide.
Brand Name : Ryzumvi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 01, 2024
Details:
Nyxol (phentolamine ophthalmic solution) is anadrenergic receptor antagonist. It is being evaluated in phase 3 clinical trials for decreased visual acuity under dim (mesopic) light conditions.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Brand Name: Nyxol
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ocuphire Gets FDA Agreement for LYNX-2 Phase 3 Trial of Phentolamine for Visual Acuity
Details : Nyxol (phentolamine ophthalmic solution) is anadrenergic receptor antagonist. It is being evaluated in phase 3 clinical trials for decreased visual acuity under dim (mesopic) light conditions.
Brand Name : Nyxol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 04, 2024
Details:
Ryzumvi (phentolamine ophthalmic solution) 0.75% is a preservative-free ophthalmic solution and a nonselective alpha adrenergic antagonist, which is investigated for Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Brand Name: Ryzumvi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Viatris
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Viatris
Deal Size : Not Applicable
Deal Type : Not Applicable
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution)...
Details : Ryzumvi (phentolamine ophthalmic solution) 0.75% is a preservative-free ophthalmic solution and a nonselective alpha adrenergic antagonist, which is investigated for Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists.
Brand Name : Ryzumvi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 27, 2023
Details:
Nyxol® is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist that inhibits the contraction of smooth muscle of the iris.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Brand Name: Nyxol
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nyxol® is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist that inhibits the contraction of smooth muscle of the iris.
Brand Name : Nyxol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 13, 2023
Details:
Nyxol® is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist that inhibits the contraction of smooth muscle of the iris.
Lead Product(s): Phentolamine Mesylate,Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Nyxol
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Lead Product(s) : Phentolamine Mesylate,Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Pre...
Details : Nyxol® is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist that inhibits the contraction of smooth muscle of the iris.
Brand Name : Nyxol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 09, 2023
Details:
Nyxol is a proprietary, preservative-free, stable, investigational eye drop formulation of phentolamine mesylate 0.75% designed to uniquely modulate the pupil size by blocking the α1 receptors found only on the iris dilator muscle without affecting the ciliary muscle.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Brand Name: Nyxol
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Re...
Details : Nyxol is a proprietary, preservative-free, stable, investigational eye drop formulation of phentolamine mesylate 0.75% designed to uniquely modulate the pupil size by blocking the α1 receptors found only on the iris dilator muscle without affecting the ...
Brand Name : Nyxol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 06, 2022
Details:
Under the terms of the license agreement, Famy will fund Nyxol (phentolamine mesylate) development through FDA approvals, that will be managed by Ocuphire, including clinical, manufacturing, and regulatory activities required for FDA approval of all three Nyxol indications.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Brand Name: Nyxol
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: FamyGen Life Sciences
Deal Size: $45.0 million Upfront Cash: $35.0 million
Deal Type: Licensing Agreement November 07, 2022
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : FamyGen Life Sciences
Deal Size : $45.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the license agreement, Famy will fund Nyxol (phentolamine mesylate) development through FDA approvals, that will be managed by Ocuphire, including clinical, manufacturing, and regulatory activities required for FDA approval of all thre...
Brand Name : Nyxol
Molecule Type : Small molecule
Upfront Cash : $35.0 million
November 07, 2022
Details:
Nyxol® is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist that inhibits the contraction of smooth muscle of the iris.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Brand Name: Nyxol
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: American Society of Ophthalmic Administrator
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 02, 2022
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : American Society of Ophthalmic Administrator
Deal Size : Undisclosed
Deal Type : Partnership
Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partne...
Details : Nyxol® is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist that inhibits the contraction of smooth muscle of the iris.
Brand Name : Nyxol
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 02, 2022
Related Excipient Companies
Excipients by Applications
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?